CardioSert

Advanced Tools for Interventional Cardiologists Performing PCI Procedures

Health Tech & Life Sciences
Acquired by Microbot Medical on May, 2018

Company Overview

Snapshot

Founded in March 2012 by Avrahan Shkalim and Noam Peleg, CardioSert operated with 1–10 employees. The company secured funding across two rounds from three investors. CardioSert was acquired by Microbot Medical in May 2018.

Business overview

CardioSert develops advanced tools for interventional cardiologists, specifically designed to support percutaneous coronary intervention (PCI) procedures. The company's core products include a proprietary guide wire for crossing complex lesions, such as chronic total occlusion (CTO), and a pressure guide wire for measuring fractional flow reserve (FFR). These technologies enable physicians to navigate arterial blockages safely and quickly, facilitating the delivery of balloon/stent catheters and providing crucial clinical decision-making data. CardioSert operates within the Health Tech & Life Sciences sector, focusing on medical devices, medical treatment, and therapeutics for healthcare providers globally.

Strategic signal

In May 2018, Microbot Medical completed the acquisition of novel technology from CardioSert. This acquisition highlights the strategic value of CardioSert's innovative tools for interventional cardiology, particularly its CTO and FFR technologies, signaling a successful exit for the company and a strengthening of Microbot Medical's product portfolio in the medical device market.

Company Intelligence Q&A

When was CardioSert acquired?
CardioSert was acquired by Microbot Medical in May 2018.
What technology did Microbot Medical acquire from CardioSert?
Microbot Medical acquired CardioSert's innovative technology, including R&D information, technical know-how, and intellectual property related to advanced tools for interventional cardiologists, in May 2019.
Which investors participated in CardioSert's July 2014 funding round?
In July 2014, CardioSert received funding from Magna Capital Partners and Medvest.
What are CardioSert's primary product offerings?
CardioSert's primary product offerings include a proprietary guide wire for crossing chronic total occlusion (CTO) and a pressure guide wire for measuring fractional flow reserve (FFR).

External links